Company: HSDTW
Filing Date: 2025-01-24
Form Type: 8-K
Source: 0001558370-25-000407
Chunk: 4

Company: Solana Co
Filing Date: 2025-01-24
Form: 8-K
Item: Item 1.01
Chunk 4
---
its.  

(d) Exhibits

  Exhibit No.      Description                                                              
 ────────────────────────────────────────────────────────────────────────────────────────────
          4.1      Form of Inducement Warrant                                               
         10.1      Form of Inducement Letter                                                
         99.1      Company Press Release dated January 21, 2025.                            
          104      Cover Page Interactive Data File (embedded within Inline XBRL document)  

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this Form 8-K are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U. S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, the Company’s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company’s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company’s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and